MENU
+Compare
BGMS
Stock ticker: NASDAQ
AS OF
Nov 13 closing price
Price
$1.34
Change
-$0.10 (-6.94%)
Capitalization
3.91M

BGMS Bio Green Med Solution Inc Forecast, Technical & Fundamental Analysis

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases... Show more

Industry: #Biotechnology
BGMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for BGMS with price predictions
Nov 12, 2025

BGMS's Stochastic Oscillator remains in oversold zone for 18 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for BGMS just turned positive on November 07, 2025. Looking at past instances where BGMS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

BGMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BGMS as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BGMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BGMS entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.077) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (212.766) is also within normal values, averaging (322.723).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BGMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BGMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BGMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EOLS7.300.31
+4.43%
Evolus
GPCR35.921.05
+3.03%
Structure Therapeutics
CAPN10.53N/A
N/A
Cayson Acquisition Corp
WYNN125.02-1.05
-0.83%
Wynn Resorts Limited
FGNX2.95-0.07
-2.32%
FG Nexus Inc.

BGMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BGMS has been loosely correlated with MBIO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BGMS jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BGMS
1D Price
Change %
BGMS100%
+2.86%
MBIO - BGMS
41%
Loosely correlated
+0.81%
CTMX - BGMS
39%
Loosely correlated
+3.17%
MIRM - BGMS
36%
Loosely correlated
-0.76%
BRNS - BGMS
31%
Poorly correlated
+1.14%
ORMP - BGMS
30%
Poorly correlated
+2.07%
More